Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
OTHER OTC:BCLI
BCLI Stock Chart & Stats
$0.60
-$0.17(-7.46%)
At close: 4:00 PM EST
$0.60
-$0.17(-7.46%)
Day’s Range― - ―
52-Week Range$0.52 - $2.50
Previous CloseN/A
Volume34.73K
Average Volume (3M)22.93K
Market Cap
$6.11M
Enterprise Value$9.41M
Total Cash (Recent Filing)$5.00K
Total Debt (Recent Filing)$326.00K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Apr 01, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding11,034,775
10 Day Avg. Volume25,343
30 Day Avg. Volume22,935
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.55
Price to Sales (P/S)14.20
P/FCF Ratio-1.33
Enterprise Value/Market Cap1.54
Enterprise Value/Revenue11.08
Enterprise Value/Gross Profit16.19
Enterprise Value/Ebitda-0.88
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Advocacy And SupportThere is growing support for NurOwn's approval, driven by media coverage and independent advocacy, including a Citizens' Petition.
Regulatory ProgressThe P3b study in ALS has been cleared by FDA, and the company plans to conduct the study under the Special Protocol Assessment.
Bears Say
Capital NeedsBrainStorm reported a net loss and will need to raise additional capital to move forward with the P3b study of NurOwn.
Financial ChallengesThe company needs to raise capital and the delisting along with the sharp decline in the share price increases the risk of an incrementally dilutive financing.
Brainstorm Cell Therapeutics News
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $0.52 and its highest was $2.50 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Brainstorm Cell Therapeutics’s market cap is $6.11M.
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 103 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on Nov 14, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.18.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Overvalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 11,034,775 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went up 11.475%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
BCLI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements towards clinical trials and strong community support, but these were overshadowed by financial challenges, NASDAQ delisting, and funding uncertainties. The sentiment is balanced between optimism for future trials and concern over current financial hurdles.View all BCLI earnings summariesTechnical Analysis
AIM ImmunoTech
―
Alaunos Therapeutics
―
Qualigen Therapeutics
―
PharmaCyte Biotech
―
Cyclerion Therapeutics
―
Ownership Overview
7.19% Insiders
0.03% Mutual Funds
1.32% Other Institutional Investors
91.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---